Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review

Paolo Gisondia Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy

https://orcid.org/0000-0002-1777-9001 View further author information

David Simonb Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany;c Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, GermanyView further author information

Ivette Alarcond Novartis Pharma AG, Basel, SwitzerlandView further author information

Effie Pournarad Novartis Pharma AG, Basel, SwitzerlandView further author information

Lluís Puige Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, SpainCorrespondence[email protected]

https://orcid.org/0000-0001-6083-0952 View further author information

Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date